198 related articles for article (PubMed ID: 14696649)
1. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer.
Kleer CG; Zhang Y; Pan Q; Gallagher G; Wu M; Wu ZF; Merajver SD
Breast Cancer Res; 2004; 6(1):R110-5. PubMed ID: 14696649
[TBL] [Abstract][Full Text] [Related]
2. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells.
van Golen KL; Wu ZF; Qiao XT; Bao L; Merajver SD
Neoplasia; 2000; 2(5):418-25. PubMed ID: 11191108
[TBL] [Abstract][Full Text] [Related]
3. Expression of WISP3 and RhoC genes at mRNA and protein levels in inflammatory and noninflammatory breast cancer in Tunisian patients.
Marrakchi R; Khadimallah I; Ouerhani S; Gamoudi A; Khomsi F; Bouzaine H; Benamor M; Bougatef K; Mnif S; Zitoun R; Benna F; Boussen H; Rahal K; Elgaaied AB
Cancer Invest; 2010 May; 28(4):399-407. PubMed ID: 20014943
[TBL] [Abstract][Full Text] [Related]
4. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype.
van Golen KL; Wu ZF; Qiao XT; Bao LW; Merajver SD
Cancer Res; 2000 Oct; 60(20):5832-8. PubMed ID: 11059780
[TBL] [Abstract][Full Text] [Related]
5. WISP3 is a novel tumor suppressor gene of inflammatory breast cancer.
Kleer CG; Zhang Y; Pan Q; van Golen KL; Wu ZF; Livant D; Merajver SD
Oncogene; 2002 May; 21(20):3172-80. PubMed ID: 12082632
[TBL] [Abstract][Full Text] [Related]
6. WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer.
Kleer CG; Zhang Y; Pan Q; Merajver SD
Neoplasia; 2004; 6(2):179-85. PubMed ID: 15140407
[TBL] [Abstract][Full Text] [Related]
7. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor.
van Golen KL; Bao L; DiVito MM; Wu Z; Prendergast GC; Merajver SD
Mol Cancer Ther; 2002 Jun; 1(8):575-83. PubMed ID: 12479217
[TBL] [Abstract][Full Text] [Related]
8. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype.
van Golen KL; Davies S; Wu ZF; Wang Y; Bucana CD; Root H; Chandrasekharappa S; Strawderman M; Ethier SP; Merajver SD
Clin Cancer Res; 1999 Sep; 5(9):2511-9. PubMed ID: 10499627
[TBL] [Abstract][Full Text] [Related]
9. Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer.
van Golen KL; Bao LW; Pan Q; Miller FR; Wu ZF; Merajver SD
Clin Exp Metastasis; 2002; 19(4):301-11. PubMed ID: 12090470
[TBL] [Abstract][Full Text] [Related]
10. Molecular determinants of the inflammatory breast cancer phenotype.
Houchens NW; Merajver SD
Oncology (Williston Park); 2008 Dec; 22(14):1556-61; discussion 1561, 1565-8, 1576. PubMed ID: 19198217
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.
Van den Eynden GG; Van Laere SJ; Van der Auwera I; Merajver SD; Van Marck EA; van Dam P; Vermeulen PB; Dirix LY; van Golen KL
Breast Cancer Res Treat; 2006 Feb; 95(3):219-28. PubMed ID: 16244790
[TBL] [Abstract][Full Text] [Related]
12. [Inflammatory breast carcinoma: towards molecular characterization?].
Charafe-Jauffret E; Tarpin C; Ginestier C; Bertucci F; Penault-Llorca F; Xerri L; Birnbaum D; Viens P; Hassoun J; Jacquemier J
Ann Pathol; 2003 Dec; 23(6):564-9. PubMed ID: 15094594
[TBL] [Abstract][Full Text] [Related]
13. RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells.
Wu M; Wu ZF; Kumar-Sinha C; Chinnaiyan A; Merajver SD
Breast Cancer Res Treat; 2004 Mar; 84(1):3-12. PubMed ID: 14999149
[TBL] [Abstract][Full Text] [Related]
14. RhoC GTPase Is a Potent Regulator of Glutamine Metabolism and N-Acetylaspartate Production in Inflammatory Breast Cancer Cells.
Wynn ML; Yates JA; Evans CR; Van Wassenhove LD; Wu ZF; Bridges S; Bao L; Fournier C; Ashrafzadeh S; Merrins MJ; Satin LS; Schnell S; Burant CF; Merajver SD
J Biol Chem; 2016 Jun; 291(26):13715-29. PubMed ID: 27129239
[TBL] [Abstract][Full Text] [Related]
15. Caveolin-1 mediates inflammatory breast cancer cell invasion via the Akt1 pathway and RhoC GTPase.
Joglekar M; Elbezanti WO; Weitzman MD; Lehman HL; van Golen KL
J Cell Biochem; 2015 Jun; 116(6):923-33. PubMed ID: 25559359
[TBL] [Abstract][Full Text] [Related]
16. The role of RhoC in ovarian epithelial carcinoma: a marker for carcinogenesis, progression, prognosis, and target therapy.
Zhao Y; Zheng HC; Chen S; Gou WF; Xiao LJ; Niu ZF
Gynecol Oncol; 2013 Sep; 130(3):570-8. PubMed ID: 23764197
[TBL] [Abstract][Full Text] [Related]
17. Analysis of RhoC expression and lymphovascular emboli in inflammatory vs non-inflammatory breast cancers in Egyptian patients.
Lo AC; Georgopoulos A; Kleer CG; Banerjee M; Omar S; Khaled H; Eissa S; Hablas A; Omar HG; Douglas JA; Merajver SD; Soliman AS
Breast; 2009 Feb; 18(1):55-9. PubMed ID: 19157876
[TBL] [Abstract][Full Text] [Related]
18. [Correlation of expression of RhoC with invasiveness of breast cancer cells in vitro].
Yuan Z; Su J; You JF; Wang JL; Cui XL; Zheng J
Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):898-903. PubMed ID: 18478927
[TBL] [Abstract][Full Text] [Related]
19. Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo.
Pillé JY; Denoyelle C; Varet J; Bertrand JR; Soria J; Opolon P; Lu H; Pritchard LL; Vannier JP; Malvy C; Soria C; Li H
Mol Ther; 2005 Feb; 11(2):267-74. PubMed ID: 15668138
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells.
Zhang Y; Pan Q; Zhong H; Merajver SD; Kleer CG
Breast Cancer Res; 2005; 7(6):R1080-9. PubMed ID: 16457688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
